BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...

BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 ...

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers since FDA approval in November 2024. The third quarter revenue totaled $120.7 million, ...

BridgeBio Pharma’s stock (BBIO) jumped over 16% after the FDA approved its cardiovascular drug, Attruby. This new treatment will compete with Pfizer’s (PFE) Vyndamax, which was extremely popular in ...

Goldman Sachs indicated it sees "additional upside" potential for BridgeBio stock as the company continues to execute its commercial strategy for Attruby in ATTR-CM (transthyretin amyloid ...

BridgeBio Pharma (BBIO), a mid-cap biotech company, has investors thrilled with its commercial engine scaling following the approval of Acoramidis (brand name Attruby), a therapy for a serious heart ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby is prescribed for adults to treat ATTR-CM. To ...

- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial ...